Table 2 Demographic and clinical characteristics of the 143 hand OA patients in randomized controlled trial 1 and 2 according to clinically significant improvement

Age, years

58.1 ± 7.5

60 ± 8.2

Female

81 (91.0)

53 (98.1)

Weight, kg

59.1 ± 8.3

59.9 ± 8.3

Height, cm

157.3 ± 5.9

155.8 ± 6.2

BMI, kg/m²

23.9 ± 2.7

24.7 ± 3.1

OA duration, month

3.2 ± 4

3.5 ± 5.1

AUSCAN Pain

43.6 ± 21.6

55.7 ± 19.7

AUSCAN Stiffness

57.5 ± 24.5

68.2 ± 20.5

AUSCAN Function

41.7 ± 23.2

49.1 ± 26.6

Patient GA

51.1 ± 16

55.6 ± 19.9

Physician GA

40.1 ± 11.3

43.7 ± 13.6

Tender JC

5.8 ± 4.7

6.5 ± 5.7

Swollen JC

0.8 ± 2.4

0.5 ± 1.5

Enlarged JC ^a

5.1 ± 2.7

5.4 ± 2.2

Deformity JC ^a

2 ± 1.6

1.9 ± 1.9

ESR

0.17 ± 0.52

0.09 ± 0.13

CRP

13.4 ± 10.4

14.5 ± 9.6

 Tramadol-AAP ^a

3 (4.6)

7 (18.9)

 Tramadol ^a

1 (1.5)

0 (0)

 NSAIDs ^a

22 (33.8)

14 (37.8)

 Diacerin ^a

2 (3.1)

1 (2.7)

 Glucosamine ^a

9 (13.8)

4 (10.8)

 Others ^a

1 (1.5)

2 (5.4)